Professor Morten Meldal was yesterday awarded the Nobel Prize in Chemistry. Morten and 2cureX's two founders, Ole Thastrup and Grith Hagel, collaborated at the Carlsberg Research Center and together invented the core technologies that were the basis for establishing 2cureX.

2cureX was spun-out of Carlsberg in 2006 with these patents that described how patient cells and drugs could be immobilized on solid support and tested for drug sensitivity. The patents have been granted in full in global territories. These initial patents created the basis for subsequent discoveries and issuance of additional intellectual property (IP), and thereby established the comprehensive and strong IP portfolio that protects the IndiTreat technology today.

Ole Thastrup, CSO & Founder of 2cureX "I would like to take the opportunity to congratulate Morten Meldal on this fantastic achievement. Morten is one of the most dedicated and innovative scientists I have met. He has a unique ability to conduct groundbreaking research and look for innovative applications. It has been an honor to work closely with Morten and to see how our early ideas and associated patents created the original basis for 2cureX".

2cureX continues to roll out its drug sensitivity tests under the CE-IVD-marked IndiTreat family. Now present in 17 countries in Europe and the near East, the company aims to change the way in which patients with metastatic colorectal cancer are treated. IndiTreat provides unique supplementary information related to a patient's sensitivity to chemotherapy, and so delivers guidance to the oncologist's treatment decision.

About 2cureX

2cureX is a leader in cancer drug sensitivity testing and has developed the IndiTreat (Individual Treatment) family of tests. Starting from a sample of the patient's tumor, IndiTreat creates thousands of 3D replicas (tumoroids) and predicts the tumor response to the different available drugs, providing the physician with valuable information to make the treatment decisions.

The first three IndiTreat tests are aimed at optimizing treatment decisions in patients with metastatic colorectal cancer (IndiTreat Start for first line of therapy, IndiTreat Extend and Explore for third line). Additional tests are under development to cover other stages of colorectal cancer as well as other gastrointestinal cancers.

According to several reports, the total yearly expenditure in cancer-related In Vitro Diagnostic (IVD) tests exceeds 17.5Bn USD worldwide, from which 2.5 Bn USD are tests directly related to therapy decision making, with a CAGR of 12.7%. Despite this, only one third of all cancer treatments are supported by one of these tests. IndiTreat aims at filling this gap and making Precision Oncology available to all cancer patients.

The company is listed on Nasdaq First North Growth Market in Stockholm (symbol: "2CUREX"). For more information about 2cureX visit www.2cureX.com

Certified Adviser: Redeye AB, +46 8 121 576 90, certifiedadviser@redeye.se

"2cureX har en betalt digital IR-aftale med Proinvestor.com